

ALEXION PHARMACEUTICALS INC  
Form 8-K/A  
January 09, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

## FORM 8-K/A

### Amendment No. 1

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 9, 2004

---

## ALEXION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or Other Jurisdiction

0-27756  
(Commission

13-3648318  
(IRS Employer

of Incorporation)

File Number)

Identification No.)

352 Knotter Drive, Cheshire, CT  
(Address of Principal Executive Offices)

06410  
(Zip Code)

Registrant's telephone number, including area code: (203) 272-2596

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

---

**Item 5. Other Events and Regulation FD Disclosure**

This Amendment No. 1 relates to the Company's Current Report on Form 8-K filed on December 18, 2003. The purpose of this amendment is to update Item 7(c).

On December 18, 2003, the Company announced its entry into a collaborative agreement with XOMA Ltd. (the Agreement) for the development and commercialization of a rationally designed human c-MPL agonist antibody to treat chemotherapy-induced thrombocytopenia.

On January 9, 2004 the Company filed with the Securities and Exchange Commission an application for confidential treatment of certain portions of the Agreement. A copy of the Agreement, with the confidential portions redacted, is filed herewith as exhibit 10.28.

**Item 7. Financial Statements and Exhibits.**

**(c) Exhibits.**

10.28 Co-Development and Co-Commercialization Agreement between Alexion Pharmaceuticals, Inc. and XOMA (US) LLC, dated as of December 17, 2003.

99.1 Press Release dated December 18, 2003.\*

---

\* Previously filed

